NJ Bio Partners with Charles River to Accelerate ADC Development
The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.
Global Pharma | 08/11/2024 | By Aishwarya | 337
Microbiologics Acquires SensID to Expand its Portfolio in Diagnostic Quality Controls
The combined expertise of Microbiologics and SensID will empower both companies to deliver a broader portfolio of quality control solutions to further support diagnostic technology developers and healthcare professionals and ultimately improve patient care worldwide.
Global Pharma | 07/11/2024 | By Aishwarya | 597
Biosynth Strengthens Leadership Team with New Appointments
Matt Gunnison will succeed Urs Spitz, under whose guidance Biosynth has achieved remarkable growth and strengthened its position in the life sciences sector.
Global Pharma | 06/11/2024 | By Aishwarya | 512
Ionis Receives FDA Approval of New Drug Application for Donidalorsen
Donidalorsen is designed to reduce the production of prekallikrein (PKK), interrupting the pathway that leads to HAE attacks.
Global Pharma | 06/11/2024 | By Aishwarya | 933
Scorpius Teams Up with Celltheon to Offer Affordable Biotherapeutics
This collaboration enables clients to integrate with Scorpius’ program management team and quality system while preparing to transfer a research cell bank (RCB) to the company’s facilities in San Antonio, TX, for further biomanufacturing work.
Global Pharma | 05/11/2024 | By Aishwarya | 433
CureVac Welcomes Axel Sven Malkomes as New Chief Financial Officer
Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries.
Global Pharma | 05/11/2024 | By Aishwarya | 486
Gland Pharma Reports Revenue of INR 14,058 Million in Q2FY25
Gland Pharma has reported a consolidated revenue of INR 14,058 million for Q2 FY25, marking a 2 percent increase compared to INR 13,734 million in Q2 FY24.
Global Pharma | 05/11/2024 | By Aishwarya | 1244
Syntegon and Abzil Close Acquisition of Telstar
The Telstar workforce will now join the Syntegon team in the Pharma Liquid Business Unit.
Global Pharma | 04/11/2024 | By Aishwarya | 1327
Lipocine Signs License Deal with SPC Korea to Commercialize TLANDO in South Korea
Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including payment upon regulatory approval of TLANDO in South Korea.
Global Pharma | 04/11/2024 | By Aishwarya | 439
Acumen Pharma Presents New Data on pTau217 Assay at Annual CTAD Conference
The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen’s Phase 1 INTERCEPT-AD trial, which did not use this approach.
Global Pharma | 01/11/2024 | By Aishwarya | 574
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy